Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics, shared on X:
“NCI Announces Availability of Botensilimab for Clinical Development
Botensilimab is available through the NCI CTEP program in collaboration with Agenus. Strong LOIs for clinical studies are being evaluated.”
Read further.
Source: Jennifer Buell/X